3rd Jul 2023
The BNA Face of the Fortnight is a new initiative, where we want to showcase the breadth, depth, and variety of neuroscience in the UK and abroad.
Dr Alan Palmer is the CEO of Elixa MediScience, a company developing novel medicines capable of both slowing neurodegenerative disease progression and delaying its onset.
Neurodegenerative diseases are a major cause of disability and premature death, and despite large efforts, 'there are very few medicines available to slow the process of neurodegeneration and thus the progression of disability". Elixa MediScience has been a part of the identification of several novel compounds and disease-modifying treatment, showcasing clear potential to making a positive impact on the life of those suffering with these debilitating diseases.
Alan Palmer is really passionate about expanding our knowledge and insight through collaboration. Here's what Alan has to say on the topic:
"Engage in interdisciplinary collaboration, expand your skill set and fully embrace translational neuroscience"
Find our more about Elixa Mediscience via their website.
If you are interested in being a BNA Face of the Fortnight, find the details here. If you have any questions then please contact BNA Digital Marketing Officer, Rachel Sellick (rachel.sellick@bna.org.uk)
Written by Rachel Sellick
BNA Digital Marketing Officer
PhD Student at Cardiff Univerisity
